118 filings
Page 2 of 6
8-K
famwp7
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
t35nw87ifdo7cucc3rb4
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
8-K
7ks4znhf97c b7
14 Sep 22
Entry into a Material Definitive Agreement
9:01am
8-K
nax 5ejw1hyj4
14 Sep 22
Other Events
7:05am
8-K
39clm m4n
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
8-K
vizbkc1
12 May 22
Departure of Directors or Certain Officers
4:10pm
8-K
nslh7 frt09fg
12 May 22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
7:12am
8-K
1nrh7li72kt3hm2
11 Apr 22
Departure of Directors or Certain Officers
4:06pm
8-K
f3qbeqt4t8316j dl28
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am
8-K
uhs7dq54i2pk
28 Feb 22
Results of Operations and Financial Condition
8:16am
8-K
qidnhriw3tb
14 Feb 22
Larimar Therapeutics Provides Update on CTI-1601 Clinical Program
12:00am
8-K
cmx176scrx bj2
12 Nov 21
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
7:21am
8-K
qz5 8yqdbof
12 Aug 21
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
10:29am
8-K
7w7py
1 Jul 21
Other Events
6:11am
8-K
490yp3
14 Jun 21
Other Events
5:21pm
8-K
hl9yih3o06rif
26 May 21
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing
10:17am
8-K
55lht6zu27vi4zzp
21 May 21
Entry into a Material Definitive Agreement
9:30am
8-K
ym62m
21 May 21
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia
7:28am
8-K
9axesf6tahrkf2ovbd
18 May 21
Other Events
3:09pm
8-K
uc31yyi2 9jsvbb60
17 May 21
Submission of Matters to a Vote of Security Holders
6:08am